Nucleic Acid Testing (NAT) Market – Trends Forecast Till 2030

Market Snapshot

Market Overview

The global Nucleic Acid Testing (NAT) Market size is projected to reach a CAGR of 7.7% from 2023-2030.

Nucleic acid testing (NAT) refers to a molecular technique for screening viruses, bacteria or pathogenic nucleic acid in the blood, tissue or urine of the patient. It is conducted for forensic testing and to diagnose transfusion-transmitted infections, genetic diseases and cancer. It involves sample pooling through nucleic acid (NA) extraction, target NA amplification and target amplicon NA detection. The testing involves kits and consumables for performing polymerase chain reaction (PCR), strand displacement amplification (SDA), ligase chain reaction (LCR), transcription-mediated amplification (TMA) and NA sequence-based amplification (NASBA) processes. NAT is also used for the identification of diseases with no visible symptoms and for resolving false reactive interpretations.

Rising usage of nucleic acid tests for the treatment of genetically related diseases, cancerous diseases, and infectious diseases caused by bacteria or viruses is anticipated to spur their demand worldwide. Apart from this, extensive use utilized for paternity testing/HLA typing and forensic testing will aid the expansion of the nucleic acid testing market in the coming years. These tests help healthcare professionals and researchers in narrowing down the period of infection. In other words, it reduces the window period between the time of serological detection of a virus and the time of viral exposure. Thus, the ability of these tests to deliver accurate results in the early detection process is likely to accelerate their demand in the forthcoming years.

The inability or difficulty of nucleic acid testing in obtaining quantitative results from a large pool of clinical sample, the difficulty of using the NAT test for susceptibility testing, and the higher cost of nucleic acid testing devices is expected to hamper the growth of the nucleic acid testing market. NAT is a highly sensitive and advanced technique; however, it is associated with high cost and requires dedicated infrastructure facility, equipment, consumables, and technical expertise thus these factors are also hindering the growth of the market.

The onset of the coronavirus disease (COVID-19) has also enhanced the demand for NAT solutions to detect antigens. NAT is widely used for the effective management of communicable diseases and accurate identification of the infecting agent.

Delvens Industry Expert's Standpoint

The Nucleic Acid Testing (NAT) market is experiencing significant growth and is expected to continue its upward trajectory in the foreseeable future. The increasing demand for accurate and reliable diagnostic testing for infectious diseases, genetic disorders, and cancer has driven the adoption of NAT technologies. The advancements in molecular diagnostics, along with the development of automated systems and high-throughput testing platforms, have further propelled the growth of the NAT market.

NAT has emerged as a powerful tool in the field of diagnostics, offering advantages such as high sensitivity, specificity, and rapid results. It has played a pivotal role in the detection and management of infectious diseases, including HIV, hepatitis, and COVID-19, facilitating early diagnosis and treatment initiation. Moreover, the growing focus on personalized medicine and precision diagnostics has expanded the application of NAT in genetic testing for inherited diseases, pharmacogenomics, and prenatal screening, among others.

Market Portfolio

Key Findings

• Nucleic acid testing (NAT) refers to a molecular technique for screening viruses, bacteria or pathogenic nucleic acid in the blood, tissue or urine of the patient. It is conducted for forensic testing and to diagnose transfusion-transmitted infections, genetic diseases and cancer. It involves sample pooling through nucleic acid (NA) extraction, target NA amplification and target amplicon NA detection. The testing involves kits and consumables for performing polymerase chain reaction (PCR), strand displacement amplification (SDA), ligase chain reaction (LCR), transcription-mediated amplification (TMA) and NA sequence-based amplification (NASBA) processes. NAT is also used for the identification of diseases with no visible symptoms and for resolving false reactive interpretations.
   
• Rising usage of nucleic acid tests for the treatment of genetically related diseases, cancerous diseases, and infectious diseases caused by bacteria or viruses is anticipated to spur their demand worldwide. Apart from this, extensive use utilized for paternity testing/HLA typing and forensic testing will aid the expansion of the nucleic acid testing market in the coming years. These tests help healthcare professionals and researchers in narrowing down the period of infection. In other words, it reduces the window period between the time of serological detection of a virus and the time of viral exposure. Thus, the ability of these tests to deliver accurate results in the early detection process is likely to accelerate their demand in the forthcoming years.
   
• The onset of the coronavirus disease (COVID-19) has also enhanced the demand for NAT solutions to detect antigens. NAT is widely used for the effective management of communicable diseases and accurate identification of the infecting agent.
   
• The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America holds a dominant position in the nucleic acid testing market. This is owing to increasing research and development studies by various government and pharmaceutical organizations in infectious disease and cancer diagnosis in North America.

Regional Analysis

North America to Dominate the Market

• North America holds a dominant position in the nucleic acid testing market. This is owing to increasing research and development studies by various government and pharmaceutical organizations in infectious disease and cancer diagnosis in North America.
   
• Furthermore, high prevalence and awareness of cancer among people, in turn opting for early detection of cancer, is expected to aid in the growth of the nucleic acid testing market in this region.

Competitive Landscape

• Abbott Laboratories
• Beckman Coulter, Inc.
• Becton
• Dickinson and Company
• BioMérieux SA
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd.
• Grifols S.A.
• Illumina, Inc.
• Novartis Ag
• Qiagen N.V.
• Quest Diagnostics Incorporated
• Siemens Ag
• Tecan Group Ltd
• Danaher
• Thermo Fisher Scientific Inc.
• Johnson & Johnson Services Inc.

Recent Developments

• In December 2021, Roche, a multinational healthcare company based in Switzerland, introduced its latest infectious disease tests on a novel molecular laboratory instrument named cobas 5800 System in countries accepting the CE mark.
   
•  11 April 2022 — Abbott, the global healthcare leader, has launched Arachitol Gummies in India, a new fruit-flavoured product for kids and adults. Arachitol Gummies are a dietary supplement that helps maintain required levels of Vitamin D sustainably. As the body needs vitamin D to absorb calcium for better bone health, keeping recommended levels of vitamin D is essential for overall well-being.

Reasons to Acquire

• Increase your understanding of the market for identifying the best and most suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends and factors.
   
• Gain authentic and granular data access for Nucleic Acid Testing (NAT) Market so as to understand the trends and the factors involved in changing market situations.
   
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
   
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope